Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11350446 | 0.73 | CYP1A2 (0.54) | FTOMAOAMAOBALDH1A1KDM4E | |
| SCHEMBL16576785 | 0.72 | FTO (0.39) | FTOMAOAMAOBALDH1A1KDM4E | |
| SCHEMBL5258668 | 0.72 | KDM4E (0.44) | ALDH1A1KDM4EMEN1KMT2ATDP1 | |
| SCHEMBL16576786 | 0.71 | LMNA (0.33) | FTOMAOAMAOBKDM4EMEN1 | |
| SCHEMBL16576781 | 0.71 | FTO (0.38) | FTOMAOAMAOBALDH1A1KDM4E | |
| SCHEMBL10968 | 0.70 | — | — | |
| Chromone SCHEMBL28394185 | 0.70 | MAOA (0.64) | FTOMAOAMAOBALDH1A1KDM4E | |
| SCHEMBL10473563 | 0.69 | IDO1 (0.43) | FTOMAOAMAOBALDH1A1KDM4E | |
| SCHEMBL15053653 | 0.69 | KDM4E (0.42) | ALDH1A1KDM4EMEN1KMT2ATDP1 | |
| SCHEMBL11350264 | 0.68 | LMNA (0.47) | FTOMAOAMAOBALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108329325-B | Synthesis method of 8-azachromone | 天津科技大学 | 2020-11-10 | — | — | CN | claimed |
| US-20220016146-A1 | METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION | Smilebiotek Zhuhai Limited (CN) | 2022-01-20 | — | — | US | disclosed |
| CN-108329325-B | Synthesis method of 8-azachromone | 天津科技大学 | 2020-11-10 | — | — | CN | disclosed |
| CN-108329325-B | Synthesis method of 8-azachromone | 天津科技大学 | 2020-11-10 | — | — | CN | disclosed |
| CN-108329325-B | Synthesis method of 8-azachromone | 天津科技大学 | 2020-11-10 | — | — | CN | disclosed |
| US-10815197-B2 | N-sulfonyl benzamides as voltage-gated sodium channel inhibitors | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2020-10-27 | — | — | US | disclosed |
| WO-2020113759-A1 | METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION | ZHUHAI QIWEI BIO-TECHNOLOGY LTD. (CN) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020113373-A1 | METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION | ZHUHAI QIWEI BIO-TECHNOLOGY LTD. (CN) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020098630-A1 | ANIMAL MODELS, SCREENING METHODS, AND TREATMENT METHODS FOR INTRAOCULAR DISEASES OR DISORDERS | ZHUHAI QIWEI BIO-TECHNOLOGY LTD. (CN) | 2020-05-22 | — | — | WO | disclosed |
| US-20190023654-A1 | N-SULFONYL BENZAMIDE DERIVATIVE WITH HETEROCYCLIC SUBSTITUENT, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-01-24 | — | — | US | disclosed |
| US-9914722-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| WO-2016124139-A1 | HETEROCYCLIC-SUBSTITUTED N-SULFONYLBENZAMIDE DERIVATIVES, PREPARATION METHOD FOR DERIVATIVES, AND PHARMACEUTICAL USE OF DERIVATIVES | 上海海雁医药科技有限公司 | 2016-08-11 | — | — | WO | disclosed |
| US-20150080383-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. | 2015-03-19 | — | — | US | disclosed |
| US-8242130-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-08-14 | — | — | US | disclosed |
| US-8093273-B2 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2012-01-10 | — | — | US | disclosed |
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2009-10-15 | — | — | US | disclosed |
| US-20060205767-A1 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | HEPALINK (HONG KONG) LIMITED (HK) | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205767-A1 | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | APOB, APOL1, FABP3 | FTO 4018/4885MAOA 251/4885MAOB 385/4885 |
| US-20150080383-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | FTO 3352/4885MAOA 1697/4885MAOB 1000/4885 |
| US-20090259048-A1 | FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, APOL1, FABP3 | FTO 4018/4885MAOA 251/4885MAOB 385/4885 |
| US-20220016146-A1 | METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION | AGER, CASP3, PDE6D | FTO 4574/4885MAOA 213/4885MAOB 133/4885 |
| US-10815197-B2 | N-sulfonyl benzamides as voltage-gated sodium channel inhibitors | SCN11A, SCN8A, NHERF1 | FTO 2567/4885MAOA 3923/4885MAOB 3568/4885 |
| US-20190023654-A1 | N-SULFONYL BENZAMIDE DERIVATIVE WITH HETEROCYCLIC SUBSTITUENT, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | SLC5A11, SLC6A11, SLC5A1 | FTO 1047/4885MAOA 2382/4885MAOB 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.